Should I buy or sell BioXcel Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares. View BTAI analyst ratings or view top-rated stocks .

What is BioXcel Therapeutics' stock price target for 2024?

7 brokers have issued 1 year target prices for BioXcel Therapeutics' stock. Their BTAI share price targets range from $4.00 to $40.00. On average, they anticipate the company's share price to reach $16.86 in the next twelve months. This suggests a possible upside of 561.1% from the stock's current price. View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts .

How have BTAI shares performed in 2024?

BioXcel Therapeutics' stock was trading at $2.95 on January 1st, 2024. Since then, BTAI shares have decreased by 13.6% and is now trading at $2.55. View the best growth stocks for 2024 here .

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a decline of 20.7% from the March 15th total of 3,140,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is currently 1.7 days. Currently, 10.5% of the company's shares are sold short. View BioXcel Therapeutics' Short Interest .

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our BTAI earnings forecast .

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.98) by $0.22. The business earned $0.38 million during the quarter, compared to analysts' expectations of $1.17 million. BioXcel Therapeutics had a negative net margin of 12,974.86% and a negative trailing twelve-month return on equity of 890.63%.

What ETF holds BioXcel Therapeutics' stock?

iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , CRISPR Therapeutics (CRSP) , JD.com (JD) , Inseego (INSG) , Marvell Technology (MRVL) , Invitae (NVTA) , Tesla (TSLA) , Advanced Micro Devices (AMD) and Editas Medicine (EDIT) .

When did BioXcel Therapeutics IPO?

BioXcel Therapeutics (BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

→ 2024's Must-Have Guide: Master Crypto Investment Today (From Darwin) (Ad)

Free BTAI Stock Alerts

$2.55

-0.04 (-1.54%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.55
▼
$2.63
50-Day Range: $1.95
▼
$3.59
52-Week Range: $1.91
▼
$29.56

Volume: 244,513 shs
Average Volume: 424,073 shs
Market Capitalization: $77.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.86

Get BioXcel Therapeutics alerts:

BioXcel Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.43 Rating Score
Upside/Downside: 561.1% Upside
$16.86 Price Target
Short Interest: Healthy
10.54% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.13
Upright™ Environmental Score
News Sentiment: 0.65
Based on 14 Articles This Week
Insider Trading: Selling Shares
$17,046 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.46) to ($1.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

126th out of 918 stocks

Pharmaceutical Preparations Industry

42nd out of 430 stocks

3.2

Analyst's Opinion

Consensus Rating
BioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
BioXcel Therapeutics has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
10.54% of the float of BioXcel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
BioXcel Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioXcel Therapeutics has recently decreased by 20.70%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BioXcel Therapeutics does not currently pay a dividend.
Dividend Growth
BioXcel Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.
Environmental Sustainability
The Environmental Impact score for BioXcel Therapeutics is -1.13.

3.1

News and Social Media Coverage

News Sentiment
BioXcel Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for BioXcel Therapeutics this week, compared to 5 articles on an average week.
Search Interest
Only 17 people have searched for BTAI on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.
MarketBeat Follows
8 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioXcel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,046.00 in company stock.
Percentage Held by Insiders
35.80% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 30.68% of the stock of BioXcel Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($2.46) to ($1.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioXcel Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioXcel Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad The Bull Report

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

About BioXcel Therapeutics Stock (NASDAQ:BTAI)

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BTAI Stock News Headlines

April 9, 2024 | insidertrades.com

Insider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Sells 5,268 Shares of Stock

April 19, 2024 | americanbankingnews.com

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus Recommendation of "Hold" from Analysts

April 19, 2024 | TradingTips (Ad)

3 Sub-$10 Stocks to Buy for 2024

Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.

April 19, 2024 | americanbankingnews.com

Q1 2024 Earnings Estimate for BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Issued By HC Wainwright

April 18, 2024 | americanbankingnews.com

Research Analysts Offer Predictions for BioXcel Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:BTAI)

April 17, 2024 | investing.com

BioXcel Therapeutics stock target cut, retains buy rating

April 17, 2024 | msn.com

BioXcel Therapeutics (BTAI) Price Target Decreased by 9.82% to 10.71

April 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Bioxcel Therapeutics Amid Strategic Clinical Trials and Regulatory Potential

April 19, 2024 | TradingTips (Ad)

3 Sub-$10 Stocks to Buy for 2024

April 12, 2024 | investing.com

BioXcel Therapeutics to begin phase 3 trial for Alzheimer's treatment

April 11, 2024 | investing.com

BioXcel Therapeutics CCO sells $2.6k in stock

April 10, 2024 | uk.investing.com

BioXcel Therapeutics CSO sells shares worth over $2.8k

April 10, 2024 | investing.com

Bioxcel Therapeutics exec sells over $400 in stock

April 10, 2024 | investing.com

BioXcel Therapeutics CEO sells shares worth over $13,000

April 10, 2024 | finance.yahoo.com

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

April 10, 2024 | globenewswire.com

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia

March 25, 2024 | globenewswire.com

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

March 24, 2024 | finance.yahoo.com

BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint

March 18, 2024 | markets.businessinsider.com

Buy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansion

March 15, 2024 | au.news.yahoo.com

Tapeworm eggs found in brain of man with penchant for 'undercooked' bacon

March 15, 2024 | markets.businessinsider.com

BioXcel Gets European Patent For Sublingual Dexmedetomidine To Treat Agitation In Dementia Patients

March 15, 2024 | markets.businessinsider.com

Bioxcel Therapeutics: Hold Rating Amid Financial and Operational Uncertainties

March 15, 2024 | tmcnet.com

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

March 15, 2024 | finance.yahoo.com

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

March 15, 2024 | globenewswire.com

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

March 15, 2024 | msn.com

FDA approves first drug for serious liver disease

March 15, 2024 | msn.com

Petco CEO Ron Coughlin steps down, ex-BestBuy exec named as replacement

See More Headlines

Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BTAI
CUSIP: N/A
CIK: 1720893
Web: www.bioxceltherapeutics.com
Phone: (475) 238-6837
Fax: N/A
Employees: 74
Year Founded: 2017

Price Target and Rating

Average Stock Price Target: $16.86
High Stock Price Target: $40.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +561.1%
Consensus Rating: Hold
Rating Score (0-4): 2.43
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-179,050,000.00
Net Margins: -12,974.86%
Pretax Margin: -12,974.86%
Return on Equity: -890.63%
Return on Assets: -144.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.65
Quick Ratio: 2.57

Sales & Book Value

Annual Sales: $1.38 million
Price / Sales: 56.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.89) per share
Price / Book: -1.35

Miscellaneous

Outstanding Shares: 30,580,000
Free Float: 19,630,000
Market Cap: $77.98 million
Optionable: Optionable
Beta: 0.40

Social Links

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Vimal D. Mehta Ph.D. (Age 62)
Founder, CEO, President, & Director
Comp: $1.76M
Mr. Javier Rodriguez (Age 51)
Senior VP, Chief Legal Officer & Corporate Secretary
Comp: $638.88k
Mr. Matthew Wiley (Age 51)
Senior VP & Chief Commercial Officer
Comp: $620.12k
Mr. Richard I. Steinhart MBA (Age 67)
Senior VP & CFO
Comp: $404k
Dr. Frank D. Yocca Ph.D. (Age 67)
Senior VP & Chief Scientific Officer
Comp: $452.58k
Dr. Vincent J. O'Neill B.Sc. (Age 55)
M.D., M.R.C.P., Executive VP and Chief of Product Development & Medical Officer
Comp: $510.17k
Dr. Chetan D. Lathia Ph.D.
Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
Dr. Robert Risinger M.D.
Chief Medical Officer - Neuroscience

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BTAI Stock Analysis - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares.
View BTAI analyst ratings or view top-rated stocks.
What is BioXcel Therapeutics' stock price target for 2024?: 7 brokers have issued 1 year target prices for BioXcel Therapeutics' stock. Their BTAI share price targets range from $4.00 to $40.00. On average, they anticipate the company's share price to reach $16.86 in the next twelve months. This suggests a possible upside of 561.1% from the stock's current price.
View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts.
How have BTAI shares performed in 2024?: BioXcel Therapeutics' stock was trading at $2.95 on January 1st, 2024. Since then, BTAI shares have decreased by 13.6% and is now trading at $2.55.
View the best growth stocks for 2024 here.
Are investors shorting BioXcel Therapeutics?: BioXcel Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a decline of 20.7% from the March 15th total of 3,140,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is currently 1.7 days. Currently, 10.5% of the company's shares are sold short.
View BioXcel Therapeutics' Short Interest.
When is BioXcel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our BTAI earnings forecast.
How were BioXcel Therapeutics' earnings last quarter?: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.98) by $0.22. The business earned $0.38 million during the quarter, compared to analysts' expectations of $1.17 million. BioXcel Therapeutics had a negative net margin of 12,974.86% and a negative trailing twelve-month return on equity of 890.63%.

What ETF holds BioXcel Therapeutics' stock?: iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio.
What other stocks do shareholders of BioXcel Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).
When did BioXcel Therapeutics IPO?: BioXcel Therapeutics (BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
How do I buy shares of BioXcel Therapeutics?: Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTAI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial